Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, …
Full TWST analysis →
Twist Bioscience Corporation ranks #35 of 62
scored companies in Diagnostics & Research by moat score — the top 56%.
The widest moat in the group is IDEXX Laboratories, Inc. (IDXX)
at 78/100.
Moat scores for companies ranked near TWST in Diagnostics & Research
How TWST scores on the Medical Devices & Diagnostics defenses
Pricing Power & Consumable Moat
Score 49
· 25% of the moat score
In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.
R&D Pipeline & Capital Returns
Score 44
· 20% of the moat score
Research spending is how a device company keeps its installed base current, but spending alone proves nothing.
FCF Quality & Cash Conversion
Score 58
· 20% of the moat score
MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.
Commercial Execution
Score 50
· 15% of the moat score
Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.
Capital Structure & Resilience
Score 62
· 12% of the moat score
Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.
Growth Durability
Score 36
· 8% of the moat score
Growth durability separates an expanding installed base from a good product cycle.
What is Twist Bioscience Corporation's moat score?
Twist Bioscience Corporation (TWST) scores 50 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #35 of 62 scored companies in Diagnostics & Research, the top 56%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 61 companies in Diagnostics & Research. Its strongest defense is Capital Structure & Resilience (62/100) and its weakest is Growth Durability (36/100).
How does Twist Bioscience Corporation compare with other Diagnostics & Research companies?
Twist Bioscience Corporation ranks #35 of 62 scored companies in Diagnostics & Research by moat score. The widest moat in Diagnostics & Research is IDEXX Laboratories, Inc. (IDXX) at 78/100. The companies ranked closest are Prenetics Global Limited (PRENW) at 50 just above it and Myriad Genetics, Inc. (MYGN) at 48 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 61 companies in Diagnostics & Research. The defenses are then weighted to produce the overall score out of 100.
Why is Twist Bioscience Corporation scored with the Medical Devices & Diagnostics template?
Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.
Which competitive defenses are measured for Twist Bioscience Corporation?
The Medical Devices & Diagnostics template measures 6 defenses, and TWST scores: Pricing Power & Consumable Moat (49), R&D Pipeline & Capital Returns (44), FCF Quality & Cash Conversion (58), Commercial Execution (50), Capital Structure & Resilience (62), Growth Durability (36). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.